In addition, the Company and Dr. Melnick entered into a consulting agreement (the “Melnick Consulting Agreement”), dated as of May 3, 2022 and effective as of the Effective Date, pursuant to which Dr. Melnick will provide consulting services to the Company for a term of ten months following the Effective Date at a rate of $11,667 per month for no more than a twenty percent (20%) work week through December 31, 2022, and thereafter at a rate of $300.00 per hour. In further consideration for Dr. Melnick’s services as a consultant, (i) all of Dr. Melnick’s options to purchase shares of the Company’s common stock and RSUs shall continue to vest during the term of the Melnick Consulting Agreement; and (ii) after the term of the Melnick Consulting Agreement ends, all of Dr. Melnick’s vested options to purchase shares of the Company’s common stock and vested RSUs will continue to be exercisable for 90 days in accordance with the terms of such options and RSUs and the 2017 Plan.
A copy of the Melnick Separation Agreement and Melnick Consulting Agreement will be filed as exhibits to the Company’s quarterly report on Form 10-Q for the quarter ending June 30, 2022, and the foregoing descriptions are subject in all respects to the actual terms of the Melnick Separation Agreement and Melnick Consulting Agreement.
Remarking on these departures, the Company’s Chief Executive Officer, Ankit Mahadevia, M.D. said “While it will be difficult to part with these talented members of our team, we want to thank them for their important contributions to Spero as we continue to pursue our mission.”
On May 3, 2022, the Company issued a press release titled “Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline”. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
Cautionary Note Regarding Forward Looking Statements
This report, including the exhibits hereto, contains forward-looking statements. These statements include, but are not limited to, statements about the potential approval of tebipenem HBr by the U.S. Food and Drug Administration (“FDA”) and the timing thereof; the potential for a partnership of the tebipenem HBr franchise; the future development and commercialization of SPR206 and SPR720; the design, initiation, timing, progress and results of the Company’s preclinical studies and clinical trials and its research and development programs; management’s assessment of the results of such preclinical studies and clinical trials; and the expected cost-savings from the Restructuring, the Company’s anticipated expenses and its anticipated cash runway. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the FDA will ultimately approve tebipenem HBr and, if so, the timing of any such approval; whether the FDA will require any additional clinical data or place labeling restrictions on the use of tebipenem HBr that would add costs for us, delay approval and/or reduce the commercial prospects of tebipenem HBr; whether any third parties would be interested in partnering with us to pursue continued efforts to obtain FDA approval of tebipenem HBr, or acquiring rights to the tebipenem HBr program from us through a partnership arrangement; the COVID-19 pandemic; the Company’s need for additional funding; the Company’s ability to successfully implement the Restructuring; the impact of the Restructuring on the Company’s business, including estimated costs related thereto; the risk that the Company may not be able to address the FDA’s concerns with respect to tebipenem HBr; the lengthy, expensive, and uncertain process of clinical drug development for SPR720 and SPR206; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; the Company’s reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; the ability to commercialize the Company’s product candidates, if approved; the Company’s ability to retain key personnel; whether the Company’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the “Risk Factors” set forth in filings that the Company periodically makes with the U.S. Securities and Exchange Commission. The forward-looking statements included in this report, including the exhibits hereto, represent the Company’s views as of the date of this report. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this report.
| Item 9.01. | Financial Statements and Exhibits. |
